Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 11/20 | 0.39 |
| ▸ | JAK2 | O60674 | 7/20 | 0.39 |
| ▸ | JAK1 | P23458 | 7/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 3/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424943 | 0.94 | ALDH1A1 (0.43) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL12424603 | 0.88 | JAK3 (0.46) | ALDH1A1MEN1MAPTKMT2AJAK3 | |
| SCHEMBL30497410 | 0.84 | JAK2 (0.40) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL24456492 | 0.84 | JAK2 (0.40) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL12424401 | 0.84 | JAK2 (0.40) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL20795819 | 0.78 | GNAI3 (0.50) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL1894338 | 0.77 | ATM (0.50) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL1899746 | 0.77 | — | — | |
| SCHEMBL12384656 | 0.77 | MEN1 (0.45) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL22142437 | 0.76 | EPHX2 (0.43) | ALDH1A1MEN1MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | ALDH1A1 1168/4885MEN1 298/4885MAPT 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.